Jessica Fye
Stock Analyst at JP Morgan
(4.58)
# 211
Out of 5,090 analysts
219
Total ratings
62.04%
Success rate
17.67%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $19.96 | +30.26% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $30.87 | -19.02% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $12.11 | +89.93% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $169.70 | +17.27% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $63.33 | +2.64% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $27.70 | -9.75% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $96.25 | +24.68% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $458.12 | +3.25% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $28.13 | +170.17% | 4 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Neutral | $73 → $89 | $102.52 | -13.19% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $53.40 | +122.85% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $205.44 | +28.50% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $455.48 | +16.36% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $322.90 | +19.23% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $81.68 | -2.06% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $46.66 | +11.46% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $68.48 | +12.44% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $29.52 | +18.56% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $204.00 | -33.82% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $489.31 | -32.56% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.59 | +71.28% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $38.78 | +28.93% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $31.97 | -6.16% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $56.90 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $11.90 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $3.73 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $16.54 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.06 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.40 | +400.00% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $27.78 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.91 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.60 | - | 1 | Feb 8, 2018 |
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $19.96
Upside: +30.26%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $30.87
Upside: -19.02%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $12.11
Upside: +89.93%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $169.70
Upside: +17.27%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $63.33
Upside: +2.64%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $27.70
Upside: -9.75%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $96.25
Upside: +24.68%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $458.12
Upside: +3.25%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $28.13
Upside: +170.17%
Incyte
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $102.52
Upside: -13.19%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $53.40
Upside: +122.85%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $205.44
Upside: +28.50%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $455.48
Upside: +16.36%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $322.90
Upside: +19.23%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $81.68
Upside: -2.06%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $46.66
Upside: +11.46%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $68.48
Upside: +12.44%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $29.52
Upside: +18.56%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $204.00
Upside: -33.82%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $489.31
Upside: -32.56%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.59
Upside: +71.28%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $38.78
Upside: +28.93%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $31.97
Upside: -6.16%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $56.90
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $11.90
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $3.73
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $16.54
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.06
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.40
Upside: +400.00%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $27.78
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.91
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.60
Upside: -